Jeong Ji-Hak, Park Sun-Jin, Dickinson Shohreh Iravani, Luo Jun-Li
Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA.
Department of Pathology, Moffitt Cancer Center, 2902 Magnolia Drive, Tampa, FL 33612, USA.
Mol Cell. 2017 Jan 5;65(1):154-167. doi: 10.1016/j.molcel.2016.11.034. Epub 2016 Dec 29.
Androgen deprivation therapy is the most effective treatment for advanced prostate cancer, but almost all cancer eventually becomes castration resistant, and the underlying mechanisms are largely unknown. Here, we show that an intrinsic constitutively activated feedforward signaling circuit composed of IκBα/NF-κB(p65), miR-196b-3p, Meis2, and PPP3CC is formed during the emergence of castration-resistant prostate cancer (CRPC). This circuit controls the expression of stem cell transcription factors that drives the high tumorigenicity of CRPC cells. Interrupting the circuit by targeting its individual components significantly impairs the tumorigenicity and CRPC development. Notably, constitutive activation of IκBα/NF-κB(p65) in this circuit is not dependent on the activation of traditional IKKβ/NF-κB pathways that are important in normal immune responses. Therefore, our studies present deep insight into the bona fide mechanisms underlying castration resistance and provide the foundation for the development of CRPC therapeutic strategies that would be highly efficient while avoiding indiscriminate IKK/NF-κB inhibition in normal cells.
雄激素剥夺疗法是晚期前列腺癌最有效的治疗方法,但几乎所有癌症最终都会发展为去势抵抗性,其潜在机制在很大程度上尚不清楚。在此,我们表明,在去势抵抗性前列腺癌(CRPC)出现过程中形成了一个由IκBα/NF-κB(p65)、miR-196b-3p、Meis2和PPP3CC组成的内在组成型激活前馈信号通路。该通路控制干细胞转录因子的表达,从而驱动CRPC细胞的高致瘤性。通过靶向其各个组件来中断该通路会显著损害其致瘤性和CRPC的发展。值得注意的是,该通路中IκBα/NF-κB(p65)的组成型激活并不依赖于在正常免疫反应中起重要作用的传统IKKβ/NF-κB通路的激活。因此,我们的研究深入洞察了去势抵抗的真正机制,并为开发高效的CRPC治疗策略奠定了基础,同时避免在正常细胞中不加区别地抑制IKK/NF-κB。